Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Tax Provisions (2021 - 2025)

Aligos Therapeutics' Tax Provisions history spans 5 years, with the latest figure at $30000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 11.11% year-over-year to $30000.0; the TTM value through Dec 2025 reached $314000.0, down 5.14%, while the annual FY2025 figure was $314000.0, 5.14% down from the prior year.
  • Tax Provisions reached $30000.0 in Q4 2025 per ALGS's latest filing, down from $56000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $757000.0 in Q2 2023 to a low of -$58000.0 in Q4 2021.
  • Average Tax Provisions over 5 years is $84350.0, with a median of $44000.0 recorded in 2021.
  • The largest YoY upside for Tax Provisions was 1510.64% in 2023 against a maximum downside of 161.22% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$58000.0 in 2021, then soared by 184.48% to $49000.0 in 2022, then plummeted by 161.22% to -$30000.0 in 2023, then skyrocketed by 190.0% to $27000.0 in 2024, then increased by 11.11% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Tax Provisions are $30000.0 (Q4 2025), $56000.0 (Q3 2025), and $185000.0 (Q2 2025).